20:40:42 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaFirst North Stockholm
Cline Scientific är verksamma inom bioteknik. Bolaget är specialiserade inom cancerdiagnostik och stamcellsterapier. Bolaget genomför utvecklingsprojekt via samarbeten med forskningsinstitutioner, där teknologin används i cellbaserade produkter och processer för att driva Life Science projekt till och genom den kliniska fasen. Bolaget har sitt huvudkontor i Göteborg och grundades under 2012.


2023-02-24 Bokslutskommuniké 2022
2022-08-26 Kvartalsrapport 2022-Q2
2022-08-17 Kvartalsrapport 2022-Q2
2022-06-10 Ordinarie utdelning CLINE B 0.00 SEK
2022-04-20 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-08-27 Kvartalsrapport 2021-Q2
2021-06-04 Ordinarie utdelning CLINE B 0.00 SEK
2021-06-03 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-08-25 Kvartalsrapport 2020-Q2
2020-02-27 Ordinarie utdelning CLINE B 0.00 SEK
2020-02-26 Årsstämma 2020
2020-02-04 Bokslutskommuniké 2019
2019-05-08 Ordinarie utdelning CLINE B 0.00 SEK
2019-05-07 Årsstämma 2019
2019-02-22 Bokslutskommuniké 2018
2018-08-10 Kvartalsrapport 2018-Q2
2018-05-03 Ordinarie utdelning CLINE B 0.00 SEK
2018-05-02 Årsstämma 2018
2018-02-23 Bokslutskommuniké 2017
2017-08-11 Kvartalsrapport 2017-Q2
2017-03-21 Ordinarie utdelning CLINE B 0.00 SEK
2017-03-20 Årsstämma 2017
2017-02-17 Bokslutskommuniké 2016
2016-11-04 Kvartalsrapport 2016-Q3
2016-08-04 Kvartalsrapport 2016-Q2
2016-05-04 Ordinarie utdelning CLINE B 0.00 SEK
2016-05-03 Kvartalsrapport 2016-Q1
2015-11-06 Kvartalsrapport 2015-Q3
2015-08-06 Kvartalsrapport 2015-Q2
2022-01-10 12:35:29

Cline Scientific AB has received clearance from the Swedish Ethical Review Authority for the collection and testing of human cartilage tissue as part of the StemCART project.  

This enables the start of ex-vivo tests to evaluate Cline's unique cells and their ability to repair cartilage. Cline can now, through its collaborating clinicians, collect samples of routinely discarded material from participating patients who are undergoing joint surgery.

The study will start immediately and is expected to continue through Q2 of 2022. It is an important validation step for StemCART. For the successful development of a cell-based product, it is essential to confirm the nature and quality of the cells that are produced. The purpose of the testing is to achieve results showing that Cline's iPS cells have successfully undergone differentiation into functional chondrocyte cells and can induce healing of cartilage tissue.  Such results will enable the further development of StemCART into a therapy product ahead of in-human clinical trials. 

About StemCART
Cline's cell-based therapy in development, StemCART, aims to repair cartilage damage with the implantation of allogeneic induced pluripotent stem cell (iPSC)-derived chondrocytes alongside a support matrix. The creation of these reparative cells is made possible by Cline's proprietary nanotechnology that enables the directed and precise differentiation of iPSCs. This gives StemCART a big market advantage as an effective allogeneic and scalable cell source for cartilage therapy.  

For more information, please contact:
Patrik Sundh, CEO
Email: patrik.sundh@clinescientific.com
Phone: +46 703-585 088